1). As a result, the most overt organ-level morbidities, such as hepatosplenomegaly, 116 peri-portal fibrosis, and subsequent portal hypertension with oesophageal varices, were 117 clearly linked to S. mansoni and S. japonicum. They thus became the primary focus of 118 population-based disease prevalence studies for intestinal forms of schistosomiasis. 119
Haematuria and renal tract pathology (bladder polyps, hydronephrosis and associations 120 to bladder cancer) were identified as complications of S. haematobium infection, and 121 these became the focus of efforts for prevention and control for this species (Bustinduy, 122 2013; Colley et al., 2014) . Unfortunately, it took over 100 years to recognize the more 123 widespread and disabling systemic morbidities of Schistosoma infection that affect the 124 youngest age groups (King & Dangerfield-Cha, 2008; Koukounari et al., 2006; 125 morbidity was eligible for treatment and this mostly occurred among older children and 148 adults (Gelfand, 1967) . 149 150 << Please insert Figure 2 here>> 151 152 In textbooks and policy literature, school-age children have been characterized 153 as the main transmitters of Schistosoma infection due to their high egg output (peaking 154 in mid-childhood between 10-15 years old) and increased water contact. Owing to their 155 "careless" water use practices, which include frequent wading, playing, and urinating or 156 defecating in or near the water, the Schistosoma transmission cycle is greatly bolstered 157 (Mott et al., 1985; Webbe, 1982) . Because detectable Schistosoma-specific morbidity due 158 to advanced organ fibrosis is mostly seen in early adulthood, children were not 159 considered as seriously affected by their infection status (Gryseels, 1989) . In addition, 160 risk for disease was erroneously believed to be related only to high-intensity infections. 161 (Gryseels, 1989; Warren et al., 1979) Recent studies across Schistosoma species have 162 discredited this paradigm by demonstrating that light-intensity infections already have 163 tangible negative health effects (Bustinduy et al., 2013; Ezeamama et al., 2005b; King, 164 2015) . 165
In the first wave of population-based morbidity surveys in the 1960s and 1970s, 166 many children were wrongly classified as 'uninfected' due to insensitive diagnostic 167 methods (i.e., eggs were not found in urine or stool), and they were termed 168 'asymptomatic' when overt anatomic morbidity was absent. (Mott, 2004; Mott & Cline, 169 1980) More refined seroprevalence studies have now demonstrated that almost all 170 children from highly endemic areas are infected by the time they reach puberty (Colley 171 et al., 2014) . Sadly, this misclassification of infection status has confounded accurate 172 burden of disease estimates and has delayed recognition of Schistosoma infection as a 173 major cause of disease/disability burden in endemic countries. (King, 2010; King, 2015) 174 Novel diagnostic assays, the Circulating Cathodic Antigen (CCA) and the Circulating 175 Anodic Antigen (CAA), which are able to detect circulating Schistosoma antigens from as 176 little as one worm pair, are now revealing clinically significant worm burdens in 177 individuals who were previously thought to be 'uninfected' based on egg-count testing. 178 (Colley et al., 2013; van Dam et al., 2015) 179
THE FIRST NUTRITIONAL STUDIES 181
The first nutritional studies in the 1980s were seminal in the field of paediatric 182 schistosomiasis. Conducted in Coastal Kenya by Stephenson and Latham, they opened 183 the door to rigorous research in this area. Epidemiological correlations were made 184 between parasitic infections, including S. haematobium, and delayed growth 185 (Stephenson et al., 1985a) . Children showed dramatic improvements in appetite and 186 physical fitness after a single dose of metrifonate, an drug effective against S. 187
haematobium that was used in that era. (Latham et al., 1990) Unfortunately, little had 188 changed in the same area of Kenya over the next 25 years, when further studies, 189 applying more accurate morbidity metrics, confirmed that decreased fitness and 190 undernutrition were still highly prevalent among children infected with S. 191 haematobium. (Bustinduy et al., 2013; Bustinduy et al., 2011). 192 Progress in this field has been slow but steady. 197 (McGarvey et al., 1992; McGarvey et al., 1996) Advances in the knowledge of host-parasite immune responses have revealed that 203 schistosomiasis is fundamentally a chronic inflammatory disease that affects the entire 204 body. This has led to much wider recognition of morbidities that are linked to the pro-205 inflammatory state that precedes fibrosis (Coutinho et al., 2006b; Leenstra et al., 2006; 206 Wamachi et al., 2004) . These so-called 'subtle' morbidities perhaps should be better 207 termed 'functional' morbidities, as they impair normal physiological functioning of an 208 infected child. The impact of infection on growth hormone (GH)/insulin-like growth 209 factor-1 (IGF-1) pathways is anabolic to the skeleton, and other inflammatory cytokines 210 also compromise bone growth (Farquharson & Ahmed, 2013) . Linear growth can be 211 severely impaired by any chronic inflammation, including inflammation caused by 212 schistosomiasis, and this, in turn, leads to childhood growth stunting. Associated anaemia of inflammation caused by infection with all species of Schistosoma impairs 214 iron storage release and utilization (Ezeamama et al., 2005b; Koukounari et al., 2006) 215 and this complication most readily manifests itself as decreased physical fitness 216 (Bustinduy et al., 2011; Friedman et al., 2005; Stephenson et al., 1985b) , poor 217 concentration, and diminished school performance (Ezeamama et al., 2005a; Jukes et al., 218 2002; Nokes et al., 1999) . If untreated, these manifestations become irreversible with 219 significant lifetime consequences: decreased work productivity as adults, altered 220 fertility in both men and women (Kjetland et al., 2012) and decreased quality of life. 221 (Terer et al., 2013) The misfortune behind the failure to recognize such 'functional' 222 morbidities is that, because they are confounded by other co-endemic diseases, 223 particularly malaria, they are often not adequately recognized as schistosomiasis- what makes schistosomiasis a 'neglected' disease (i.e., counted among the NTDs) is that 237 its perceived importance to health has been linked to its disability-adjusted life-year 238 (DALY) ranking in the WHO-World Bank Global Burden of Disease (GBD) system. In its 239 first iteration, the GBD program intentionally weighted disease impact by age, giving 240 much greater emphasis to diseases that affect 20-30 year olds, and much less to 241 diseases of children under five (Murray CJ, 1996) . While this error has been corrected in 242 more recent GBD versions (Salomon et al., 2012; Vos et al., 2012) schistosomiasis has 243 always been assigned the health impact associated with 'minor infections' and given a 244 negligible 0.004-0.005 disability weight. Thus, although there are more than 250 million 245 persons with active (egg-positive) cases, and likely an equivalent number of people with 'egg-negative' Schistosoma-related disease, the calculated worldwide DALY impact of 247 schistosomiasis is perceived as less than one-tenth of that attributed to other, more 248 lethal diseases of childhood. In the eyes of many donors and policymakers, this lowers 249 its priority for control and prevention. 250
251
To correctly assess the disease burden of Schistosoma infection it is important to 252 recognize the lifetime cumulative impact of infection, not just in terms of individual 253 organ pathology and dysfunction, but also on the overall whole-body performance of 254 the growing child and young adult. Schistosomiasis that causes chronic anemia, growth 255 faltering, and poor cognitive performance is quite disabling in a setting where resources 256 are limited, and accommodation for disabilities is inadequate. Disease impact does not 257 end when Schistosoma infection ends, and the associated loss of schooling and/or 258 reduced growth cannot be reversed by childhood treatments if rapid reinfection is likely 259 where a child lives, plays, and works. Similarly, these losses cannot be reversed once a 260 person reaches adulthood. Once the child passes school age, most of these functional 261 pathologies become irreversible. 262
EARLY YEARS (< 5 YEARS OF AGE) 264
The institutional apathy regarding treatment of schistosomiasis in children under six is 265 in stark contrast to the recommendations for treatment of preschool children infected 266 with soil-transmitted helminths, a practice that has been at the forefront of paediatric 267 care and treatment campaigns for many years (World Health Organisation, 2007) . 268
Children under five years of age are often daily exposed to infected water very early in 269 life, and although initial infection occurs 'silently', it generates inflammation that 270 predisposes to organ fibrosis, which will then endure for decades (Colley et al., 2014) 271 which disease among very young children was described, but then appears to have been 273 forgotten in subsequent formulation of action plans (Mott, 1982) . The justification for 274 this health policy gap was two-fold; firstly, young children were considered a lightly-275 infected population and therefore thought to be at low-risk for schistosomiasis-276 associated morbidity; secondly, there was no child-friendly formulation for oral 277 treatment that would decrease the risk of choking. Crushing tablets to treat younger 278 children was not considered practical for national programmes, although this approach is widely performed for pill treatment of other diseases such as tuberculosis (Pineiro 280 Perez et al., 2016) . In essence, the under-fives weren't seriously considered at risk and 281 they were deemed too difficult and unsafe to treat, so they were excluded. It wasn't until 282 2010 that the first expert meeting on the inclusion of preschool children in 283 schistosomiasis control efforts was convened at the World Health Organisation (WHO). 284 (World Health Organization., 2011) 285 286 << Please insert Figure 4 here>> 287 288 From a modern perspective, stronger evidence is emerging that very young 289 preschool children do indeed harbor egg-patent infection. (Bosompem et al., 2004; 290 Odogwu et al., 2006; Sousa-Figueiredo et al., 2008; Verani et al., 2011) and also present 291 with early fibrosis, including hepatosplenic disease due to S. mansoni and early bladder 292 changes due to S. haematobium (Fig 5) . Detection of these early fibrotic changes 293 however, may prove challenging. The first injectable anti-schistosomal treatment, potassium antimony tartrate, or tartar 310 emetic (TE), which contained trivalent antimony, was introduced in 1918 as a drug 311 initially used to treat visceral leishmaniasis. (Christopherson, 1924) (Figure 1) Although promising at first, it had very limited efficacy and severe side effects (Jordan, 313 2000) . Other drugs followed, including hycanthone, and oral niridazole each with 314 severe side effects and difficulties in administration. Since 1984, praziquantel (PZQ), the current drug of choice, has displaced older drugs of 320 lesser effectiveness for all types of schistosomiasis. (Doenhoff et al., 2008; King et al., 321 1988; King & Mahmoud, 1989 ) Its full mechanism of action remains unclear, but it is 322 thought to act on the calcium ion channels of schistosome's tegument leading to 323 disruption of the parasite's surface, and exposing it to lethal damage by the host's 324 immune system (Doenhoff et al., 2008) . Adult dose finding studies in the 1970's and 325 1980's concluded that a single PZQ dose of 40 mg/kg was effective for treating S. 326 haematobium and S. mansoni (Davis et al., 1979; Davis & Wegner, 1979; King et al., 327 2002) . However, in highly-endemic areas, a more intense, repeated dosing approach is 328 likely needed for optimal effect, particularly for S. mansoni (King et al., 2011) . 329 330 Since its introduction in the 1980s, praziquantel has been used safely in children. 331
However, their recommended dosages were directly extrapolated from 332 pharmacokinetic studies performed in adults (Kabatereine et al., 2007; Mutapi et al., 333 2011; Xiao, 2005) . Work in Uganda in 2010 revealed sub-optimal PZQ cure rates for S. 334 mansoni among preschool children (Sousa-Figueiredo et al., 2010) . To explore the 335 appropriateness of age-adjusted dosing, the first pharmacokinetic/pharmacodynamic 336 PZQ study in children in Uganda was conducted in that same area. Results from this 337 recent study showed a very concerning risk of underdosing of children, particularly the 338 younger ones, if standard 40 mg/kg was given. Higher doses may be needed for treating 339 these and other children infected with S. mansoni. (Bustinduy et al., 2016a) The success of schistosomiasis control programmes has been very uneven over the last 363 century. Efficacy has varied largely depending on the baseline prevalence of infection. 364 (Jordan, 2000; Wang et al., 2008) , Success stories in Japan, Morocco, (Amarir et al., 365 2011 ) Iran, and Tunisia give hope to less developed countries that are confronted by the 366 'trap' of self-perpetuating, disease-related poverty (Sacks, 2005) . Economically 367 disadvantaged countries are only just now starting to prioritize NTD control (Savioli et 368 al., 2009) . To date, implementation of large-scale control efforts in highly endemic areas 369 has not shown permanent success, likely due to ecological factors favoring transmission 370 and human reinfection. Part of the unfortunate lack of success of many control efforts 371 stems from the complex reality of a disease that involves social interactions in hot spots 372 of high transmission. Campaigns frequently miss 'super-spreaders'-children and 373 individuals highly infected who act as reservoirs (King, 2009 ). The risk of reinfection or 374 're-worming' in high-transmission villages in Kenya was found to be as high as 50 % 375 over two years despite ongoing school-based MDA (Satayathum et al., 2006) . Even more 376 disheartening was the return to high prevalence in the same areas after control efforts 377 were interrupted for 8 years. (Wang et al., 2012) Older control interventions, based on better access to clean water and the use of molluscicides, may still have important 379 adjuvant roles to play as part of adaptive strategies in implementing more effective 380 schistosomiasis control programs. (Fenwick et al., 2009; Garba et al., 2009) 381 382 The WHO estimates that in the 52 countries in need of schistosomiasis control, 383 over 123 million of school-age children need preventive chemotherapy, out of which 384 only 43 million school age children (34.6 %) may actually receive it. (World Health  385 Organization., 2016) Therefore, there is a large treatment gap remaining among this age 386 group. Because current control strategies primarily target children who attend school, 387 those remaining at home, often with more severe disease, don't necessarily receive 388 treatment from MDA. A vicious cycle of heavier infection and more severe morbidity 389 ensues (Stothard, 2013; Stothard et al., 2011) . This double treatment gap (preschool 390 children and absent school age children) is a health inequality that should be a priority 391 in control program planning and implementation. Ambitious goals set by the WHO 2012 392 roadmap (Stothard et al., 2014; World Health Organization., 2012) have increased 393 funding and raised the profile of schistosomiasis control, but this leaves a long road 394 ahead for true elimination. 395
CONCLUSIONS 397
While there has not been a failure to recognize early childhood Schistosoma-related 398 disease, treatment strategies have not been focused on this phase of infection and its 399 spectrum of disease. It is time for this to change. While MDA continues to lower 400 Schistosoma prevalence, the residual morbidity is significant and persistent low-level 401 worm burdens hinder the plans for elimination in many endemic areas. A more 402 comprehensive integrated management of schistosomiasis, including effective MDA of 403 both preschool and school age children, needs to be adopted as a better strategy for 404 control. 405
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